Introduction:This investigation was aimed to determine the function of bupropion in neuropathic pain (NP) symptoms in an animal model and to investigate the possible role of adrenergic receptors (ARS) and dopaminergic receptors (DRS) on the analgesic effects of bupropion, we used yohimbine and haloperidol. A chronic constriction injury (CCI) model of the sciatic nerve was performed to induce NP in rats, resulting in hyperalgesia and allodynia. Methods and Materials: We administrated bupropion (3, 10, and 30 mg/kg i.p) on days 3–21 post-surgery to examine the effect of bupropion on the development of NP. Behavioral tests were performed on the 7th, 14th, and 21st day post-CCI. To determine the role of ARS and DRS in the antinociceptive effects of bupropion, animals were treated with yohimbine (3mg/kg i.p) and haloperidol (0.03mg/kg i.p) at day 7, 14, and 21, alone and with bupropion. Results: Administration of bupropion (3, 10, and 30 mg/kg) decreased hyperalgesia and mechanical allodynia significantly compared to the CCI group. While could not reduce thermal allodynia. The effect of bupropion (30 mg/kg) on hyperalgesia, and thermal and mechanical allodynia was reversed by pretreatment with yohimbine. While haloperidol only reversed the effect of bupropion on mechanical allodynia. Conclusion: This investigation suggests that bupropion can reduce pain caused by sciatic nerve injury. Also, we indicated that adrenergic and dopaminergic receptors intervene in the analgesic effects of bupropion.
Mirabzadeh Fini R, Hamidi G A. Effect of Bupropion on neuropathic pain behavior in a rat model of chronic constriction injury (CCI): Role of Adrenergic and dopaminergic receptors. Koomesh 2023; 25 (5) :376-376 URL: http://koomeshjournal.semums.ac.ir/article-1-8543-en.html